⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30401299 | 0.81 | — | — | |
| SCHEMBL344526 | 0.72 | CYP2C9 (0.72) | — | |
| SCHEMBL65120 | 0.69 | CYP2C19 (0.68) | — | |
| SCHEMBL28794300 | 0.69 | — | — | |
| SCHEMBL347138 | 0.69 | CYP2C19 (0.68) | — | |
| SCHEMBL23344393 | 0.69 | — | — | |
| SCHEMBL48539 | 0.69 | — | — | |
| Bromide SCHEMBL38656355 | 0.69 | CYP2C9 (0.68) | — | |
| SCHEMBL16258964 | 0.69 | — | — | |
| SCHEMBL21245481 | 0.67 | CA2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017125870-A1 | AMINE DERIVATIVES OF LUPANES WITH HIV MATURATION INHIBITORY ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-27 | — | — | WO | disclosed |
| EP-2695608-B1 | Lipid containing formulations | ARBUTUS BIOPHARMA CORP (CA) | 2016-11-23 | — | — | EP | disclosed |
| US-20150209447-A1 | CROSSLINKED POLYMER NANO-ASSEMBLIES AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2015-07-30 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1183020-B1 | (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) FOR THE TREATMENT OF INSULIN RESISTANCE AND TYPE 2 DIABETES | METABOLEX INC (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |